β-lactam antibiotic

Centrient Pharmaceuticals boosting statins API manufacturing capacity

Retrieved on: 
Monday, June 21, 2021
Health sciences, Health care, Health, Hepatotoxins, Pharmaceutical industry, Statin, Pharmaceuticals policy, Beta-lactam, β-lactam antibiotic, Pharmaceutical industry in China, Medication

Centrient Pharmaceuticals has started production at its newly built statins API manufacturing unit in Toansa, India.

Key Points: 
  • Centrient Pharmaceuticals has started production at its newly built statins API manufacturing unit in Toansa, India.
  • Using backward integrated manufacturing methods, and dedicated production facilities, Centrient Pharmaceuticals is able to offer its customers security of supply.
  • Centrient Pharmaceuticals (Centrient), the global leader in sustainable antibiotics, next-generation statins and anti-fungals, announced today to have started production at its new statins manufacturing unit.
  • Centrient Pharmaceuticals is the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and antifungals.

Qpex Biopharma Initiates Phase 1 Study of ORAvance™ for Oral Treatment of Drug-Resistant Gram-Negative Bacterial Infections

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Beta-lactam antibiotics, β-lactam antibiotic, β-Lactamase inhibitor, Beta-lactamase, Biomedical Advanced Research and Development Authority, Beta-lactamase inhibitors, Antibiotics, Biocides, Drugs, Infectious diseases, Penicillins

The World Health Organization (WHO) has also prioritized development of new treatments for these pathogens.

Key Points: 
  • The World Health Organization (WHO) has also prioritized development of new treatments for these pathogens.
  • Two of the products use QPX7728, an ultra-broad-spectrum beta-lactamase inhibitor that restores the potency of beta-lactam antibiotics in vitro and in vivo.
  • Qpex\xe2\x80\x99s current collaboration with BARDA is focused on advancing a portfolio of novel antibiotics, including the QPX7728-based products OMNIvance and ORAvance.
  • For more information, please visit www.qpexbio.com and follow us on Twitter and LinkedIn .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005284/en/\n'

Centrient Pharmaceuticals to acquire Astral SteriTech, expanding its product portfolio with sterile injectable antibiotic finished dosage forms

Retrieved on: 
Monday, February 15, 2021
Chemical compounds, Organic compounds, Penicillins, Branches of biology, Microbiology, Penicillium, Cephalosporin, β-lactam antibiotic, Beta-lactam, Antibiotic, Production of antibiotics

The products offered by Astral SteriTech are sterile injectable finished dosage forms for Semi-Synthetic Cephalosporins and Semi-Synthetic Penicillins.

Key Points: 
  • The products offered by Astral SteriTech are sterile injectable finished dosage forms for Semi-Synthetic Cephalosporins and Semi-Synthetic Penicillins.
  • Being close to Centrients core products of beta-lactam antibiotics, the acquired product portfolio provides Centrient a diversification opportunity within the attractive growing niche segment of sterile injectable antibiotics.
  • With the broadened product portfolio, Centrient can further meet the needs of its customers in Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin finished dosage forms and become the preferred partner in these segments.
  • Astral SteriTech is a leading international contract manufacturer specialized in sterile antibiotic powder injectable finished dosage forms.

Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant Bacterial Infections

Retrieved on: 
Thursday, December 3, 2020
Biotechnology, Pharmaceutical, General Health, Health, Infectious diseases, Hospitals, Clinical trials, Other Health, Chemical compounds, Organic compounds, β-Lactamase inhibitor, Chemistry, Beta-lactamase, Beta-lactamase inhibitors, Antibiotics, β-lactam antibiotic, Beta-lactam, Carboxylic acids, Drug resistance, Discovery and development of cephalosporins, QPX7728, Biomedical Advanced Research and Development Authority (BARDA) Partnership, Brii Biosciences Partnership, Antimicrobial Resistance (AMR), Qpex Biopharma

Today marks another important milestone for Qpex as we begin advancing three novel product candidates into clinical trials during the coming months, said Michael Dudley, Pharm.D., president and chief executive officer of Qpex Biopharma.

Key Points: 
  • Today marks another important milestone for Qpex as we begin advancing three novel product candidates into clinical trials during the coming months, said Michael Dudley, Pharm.D., president and chief executive officer of Qpex Biopharma.
  • We believe that QPX7728 has demonstrated a preclinical profile that exceeds that of recently marketed beta-lactamase inhibitors, as well as those in ongoing clinical trials.
  • Beta-lactamases are bacterial enzymes that destroy beta-lactam antibiotics and are the major mechanism of resistance to these drugs in gram-negative bacteria.
  • Qpex has a multi-product collaboration with Brii Biosciences for the development and commercialization of three of its products in greater China.